Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC3927 in Chronic Obstructive Pulmonary Disease
NCT07633314Phase 2Suspended
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of TQC3927 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Area under the FEV1 curve at 14 days. Planned start Dec 2026; status: suspended.
02
Drugs
TQC3927
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07633314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633314.